Argent BioPharma Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	0.18	0.89	3.39	4.73	3
Revenue Growth (YoY)	-79.74%	-73.69%	-28.41%	57.94%	44.10%
Cost of Revenue	0.78	1.2	2.04	4.17	1.9
Gross Profit	-0.6	-0.3	1.35	0.56	1.1
Selling, General & Admin	12.12	15.56	13.34	11.83	7.79
Research & Development	3.59	2.32	2.99	-	-
Other Operating Expenses	-0.67	-0.16	0.22	4.23	5.25
Operating Expenses	15.04	17.72	16.56	16.06	13.04
Operating Income	-15.64	-18.02	-15.21	-15.5	-11.94
Interest Expense	-0.05	-0.48	-0.26	-0.21	-0.37
Interest & Investment Income	0	0	0	0	0.01
Currency Exchange Gain (Loss)	0.36	0.83	-1.22	0.08	-0.03
Other Non Operating Income (Expenses)	-	0.06	0.09	-1.24	-3.57
EBT Excluding Unusual Items	-15.33	-17.61	-16.6	-16.86	-15.9
Impairment of Goodwill	-	-	-3.15	-3.9	-
Gain (Loss) on Sale of Investments	-1.41	1.34	-1.39	-	-
Gain (Loss) on Sale of Assets	-0.12	-0.02	-	-	-
Asset Writedown	-0.98	-1.26	-	-	-
Pretax Income	-17.84	-17.55	-21.13	-20.77	-15.9
Income Tax Expense	-	-	0	-	-0.03
Earnings From Continuing Operations	-17.84	-17.55	-21.13	-20.77	-15.87
Net Income to Company	-17.84	-17.55	-21.13	-20.77	-15.87
Minority Interest in Earnings	-	0.02	0.31	0.42	0
Net Income	-17.84	-17.53	-20.82	-20.35	-15.87
Net Income to Common	-17.84	-17.53	-20.82	-20.35	-15.87
Shares Outstanding (Basic)	57	37	3	3	2
Shares Outstanding (Diluted)	57	37	3	3	2
Shares Change (YoY)	54.47%	1155.86%	14.85%	34.63%	37.91%
EPS (Basic)	-0.31	-0.47	-7.07	-7.93	-8.33
EPS (Diluted)	-0.31	-0.47	-7.10	-7.93	-8.33
Free Cash Flow	-9.28	-14.8	-12.18	-14.85	-15.32
Free Cash Flow Per Share	-0.16	-0.40	-4.13	-5.79	-8.04
Gross Margin	-	-34.13%	39.88%	11.89%	36.70%
Operating Margin	-8663.31%	-2022.52%	-448.91%	-327.54%	-398.48%
Profit Margin	-9882.48%	-1967.34%	-614.71%	-430.00%	-529.70%
Free Cash Flow Margin	-5140.45%	-1661.19%	-359.40%	-313.85%	-511.23%
EBITDA	-15.08	-16.95	-14.67	-15.4	-11.6
D&A For EBITDA	0.56	1.08	0.54	0.1	0.34
EBIT	-15.64	-18.02	-15.21	-15.5	-11.94

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.